Move to topTop
May 10, 2012

Terumo Corporation (TOKYO: 4543) approved, at the meeting of its Board of Directors held on May 10, 2012, the year-end dividends for the fiscal year ended March 31, 2012 as follows:

1. Details of Year-End Dividends

Details of resolution

Latest dividend forecast

(as of May 11, 2011)

FY 2010

Year-end dividends (Actual)

Record date March 31, 2012 March 31, 2012 March 31, 2011
Dividend per share ¥22.00 ¥17.00 ¥18.00
Total amount of dividends ¥4,177 million - ¥3,417 million
Dividend payment starting date June 29, 2012 - June 30, 2011
Source of dividends Retained earnings - Retained earnings

2. Reasons for Determination of Dividend Amount

Our basic policy for profit allocation is to stably increase dividends to shareholders in accordance with business performance, investment plan and other aspects. In order to clarify the policy, the management will aim for the target dividend payout ratio of 30% over the medium to long term with the objective to increase returning profit to shareholders.

(Reference) Dividend Forecast and Actual

Dividend per share
Record date Interim dividend Year-end dividend Annual dividend (total)
Revised forecast - ¥22.00 ¥39.00

FY 2011

(ended March 31, 2012)

¥17.00 - -

FY 2010

(ended March 31, 2011)

¥16.00 ¥18.00 ¥34.00

Note: The revised dividend for the year-end will be adopted on the condition of approval from shareholders in the general shareholders' meeting to be held on June 28, 2012.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.